Veracyte, Inc. — 2018 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2018; it also reports fourth-quarter results. Veracyte develops and provides genomic diagnostic tests, principally Afirma for thyroid nodules, Percepta for lung cancer diagnosis, and Envisia for interstitial lung disease. Revenue is predominantly U.S.-based and historically driven by Afirma.
Financial performance and liquidity
- Revenue: Q4 revenue was $25.8 million, up 31% year over year. Full-year revenue was $92.0 million, up 28% from $72.0 million. Growth reflected 22% higher reported genomic test volume and improved Afirma reimbursement accrual rates.
- Volume and margins: Full-year reported genomic test volume rose 22% to 31,710; Q4 volume was 9,154, up 28%. Gross margin was 66% in Q4 and 64% for the year; the filing reports increases of 6% and 3%, respectively.
- Expenses and earnings: Full-year operating expenses excluding cost of revenue were $81.2 million, up 15%. Operating loss narrowed to $22.2 million from $26.5 million; net loss improved to $23.0 million from $31.0 million. Basic and diluted loss per share was $0.62, versus $0.91. Q4 net loss was $3.1 million, versus $8.4 million a year earlier.
- Cash flow: Net cash used in operating activities was $13.5 million for 2018, compared with $23.9 million in 2017. Company-defined cash burn was $15.4 million, compared with $25.2 million. Capital expenditures were $1.9 million.
- Liquidity and debt: Cash and cash equivalents were $78.0 million at year-end; working capital was $83.9 million. Debt principal was $25.0 million at year-end, with $25.3 million net debt obligation reported on the balance sheet. In January 2019, the company prepaid $12.5 million of principal, reducing the principal balance to $12.5 million. The company said available cash, its credit line and anticipated revenue should cover requirements for at least the next 12 months.
- Other balance-sheet measures: Total assets were $120.6 million, total liabilities $40.9 million, and stockholders’ equity $79.8 million. Accumulated deficit was $234.1 million.
Material changes and business developments
- Afirma GSC customer transition was completed in 2018; 30% of Afirma GSC orders included the newly launched Xpression Atlas.
- Percepta recorded nearly 1,550 tests in its first full year of commercialization, with volume up 74% sequentially in Q4. Envisia had 20 early-access sites; nationwide commercial expansion was planned for 2019.
- Veracyte raised approximately $55.0 million net in a July 2018 public offering of 5.75 million shares, increasing the share count.
- The company entered a lung-diagnostics collaboration with Johnson & Johnson in December 2018. Veracyte estimated its combined monetary and non-monetary value at more than $50 million; no performance obligations or consideration had occurred by year-end. A separate Loxo Oncology research collaboration provided access to Afirma Xpression Atlas data.
- Medicare issued draft positive coverage for Envisia; final coverage was expected in early 2019, but was not assured. The Afirma Medicare rate was $3,600 and Percepta’s was $3,220 at year-end.
Outlook, risks and unusual items
- Management gave no specific numerical revenue or earnings guidance in the provided filing text. It expects further operating losses and continued investment in research, sales, marketing and commercialization; it also stated that year-end liquidity was expected to fund at least 12 months of anticipated needs.
- Austin laboratory CLIA status: CMS inactivated Veracyte’s Austin laboratory CLIA number effective July 2018, determining that Veracyte did not require a certificate for its role there. The company sought reinstatement. If certification were not made effective from July 2018, Veracyte could have to reverse about $1.5 million of 2018 revenue and remit about $1.0 million previously collected; failure to reinstate could prevent Medicare billing for affected cytopathology services.
- Revenue-estimation risk: Test revenue is recognized using estimates of expected collections. 2018 collection-estimate changes added $2.0 million to revenue, of which $1.5 million had been collected by year-end. The filing also reports $159.3 million of historical tests billed at list price but not recognized as revenue as of December 31, 2017; none of that amount was collected during 2018. This figure is not reported as recognized revenue or accounts receivable.
- Concentration and reimbursement: Medicare and UnitedHealthcare represented 29% and 12% of 2018 revenue, respectively. Payer coverage, reimbursement rates, claims denials and collection timing remain material risks. The company also relies on TCP for thyroid cytopathology and on sole-source suppliers for certain laboratory materials.
- Debt and financing: The loan agreement is secured by substantially all assets except intellectual property, has restrictive covenants and requires specified revenue levels, subject to a $40 million liquidity alternative. The company reported compliance at year-end. Continued losses may require additional financing, which could dilute shareholders or add restrictions.
- Regulatory and operating risks: Potential changes to FDA oversight of laboratory-developed tests, CLIA or payer rules could raise costs, delay products or affect reimbursement. The filing identifies no material pending litigation. The financial statement auditor gave an unqualified opinion, and management and the auditor reported effective internal control over financial reporting.
Key facts investors should verify
- Whether CMS reinstated the Austin CLIA certificate, its effective date, and any resulting revenue reversal or repayment.
- Whether Envisia received final Medicare coverage and the resulting payment rate and commercial uptake.
- Whether Afirma reimbursement accruals convert into cash as estimated, and how collection experience affects future revenue adjustments.
- Whether test-volume growth and gross-margin improvement persist as Percepta and Envisia scale and Afirma platform transition costs subside.
- Post-prepayment debt principal, available revolving credit, covenant compliance and cash runway as operating losses continue.
- The dilution and use of proceeds from the 2018 offering, and any material economics or milestones under the Johnson & Johnson collaboration.